VIENNA, Austria--(BUSINESS WIRE)--Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that its collaborative research partners in Japan, headed by Dr. Hideki Hasegawa, M.D., Ph.D., will present new data on augmentation of influenza vaccines using Hemispherx’s Vaccine Enhancement Drug platform.
